ALACHUA, FL--(Marketwired - July 18, 2016) - CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that the company has been invited to present on its clinical and drug development program for its orphan drug Trappsol® Cyclo™ at the 7th Interactive Workshop on Niemann-Pick Diseases and 23rd Family Conference. The workshop and conference are hosted by the Niemann-Pick UK charity. CTD will discuss progress in its clinical program using Trappsol® Cyclo™ intravenously in the treatment of Niemann-Pick Type C (NPC) disease.
The events, held September 16-18, 2016 at Wyboston Lakes, Bedforshire, UK., bring NPC patients, families, caregivers and scientists together to hear about advances in drug development and research and to provide opportunities for community learning, sharing and support.
In addition to its formal presentations, CTD has been invited to organize a workshop for families as part of the Family Conference. The company's workshop will include a meeting of its Family and Physicians Listening Circle.
About the Company:
CTD Holdings, Inc. is a biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company's Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company's website: www.ctd-holdings.com
Safe Harbor Statement:
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.